11 September 2023 - PDUFA target goal date set for 28 April 2024. ...
11 September 2023 - PDUFA target action date of 26 June 2024. ...
22 August 2023 - Geron Corporationtoday announced that the US FDA has assigned a standard review and a PDUFA action date ...
21 August 2023 - While lagging other regulators in bringing new drugs to market, Swiss regulators say their review times ...
14 August 2023 – Valneva today announced that the US FDA has revised the PDUFA action date for the biologics ...
26 June 2023 - UCB today announced that the biologics license application for bimekizumab for the treatment of adults with ...
20 June 2023 - Additional time needed for labelling and post-marketing requirements discussions; PDUFA date set for 19 September 2023. ...
16 June 2023 - GSK today announced that the US FDA has extended the review period of the new drug application ...
5 June 2023 - FDA extending PDUFA date by three months to allow more time to complete their review; new ...
20 April 2023 - Daiichi Sankyo today announced that the US FDA has extended the review period for the new ...
7 March 2023 - FDA extends PDUFA target action date to 30 June 2023. ...
24 February 2023 - Celltrion has come forward to explain reasons for the delayed approval of its Humira biosimilar, Yuflyma ...
20 February 2023 - Astellas Pharma today announced the US FDA notified the company that it is extending the original priority ...
17 February 2023 - Eisai anticipates about 100,000 patients diagnosed will be eligible for the drug by year three of its ...
16 February 2023 - EMA marketing authorisation application for leniolisib changed to standard review timetable. ...